Company intelligence / Profile preview

AegisCN LLC

Ownership: Private
Development stage: Other

Overview

Completed a Phase 2, randomized, double-blind, placebo-controlled study evaluating CN-105 in patients with supratentorial intracerebral hemorrhage (ICH). The study involved 30 active participants and 30 control participants receiving CN-105 or placebo intravenously every 6 hours for up to 3 days.

Therapeutic areas: Neurology
Modalities: Peptides
Industry: Biotech

Drug pipeline

1 asset

CN-105

Partnerships

Duke University

Beyond the preview

Go deeper on AegisCN LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AegisCN LLC.

Explore the full profile